Treatment
What CPTSD is, how buprenorphine works, and what patients should know.
What is CPTSD?
Complex Post-Traumatic Stress Disorder (CPTSD) is a condition that develops in response to prolonged, repeated trauma — particularly when escape was impossible. People with CPTSD experience persistent emotional dysregulation, disrupted relationships, and a deeply altered sense of self, alongside the core symptoms of PTSD. Because repeated inescapable stress reshapes how the nervous system responds to threat and safety, the effects extend far beyond memory and fear.
CPTSD is often misread as “just PTSD,” or conflated with personality disorders that share overlapping features. In reality, it reflects distinct neurobiological adaptations to chronic trauma — adaptations increasingly understood to involve dysregulation of the brain’s stress response systems, including the endogenous opioid system.
ICD-11 diagnostic criteria
CPTSD is recognized in the ICD-11, which describes it as PTSD plus a distinct cluster called Disturbances in Self-Organization (DSO). Both clusters must be present.
PTSD cluster — all three required:
- Re-experiencing the traumatic event in the present (intrusive memories, flashbacks, nightmares)
- Deliberate avoidance of reminders of the event
- Persistent perception of heightened current threat (hypervigilance, exaggerated startle response)
Disturbances in Self-Organization (DSO) — all three required:
- Affect dysregulation — severe, persistent difficulty regulating emotional responses, which may include emotional numbing, explosive anger, or dissociative episodes
- Negative self-concept — persistent beliefs about oneself as diminished, defeated, or worthless, accompanied by deep shame, guilt, or failure
- Disturbances in relationships — persistent difficulty sustaining relationships or feeling close to others
How to know if you might have CPTSD
Diagnosis is based on a clinical interview, usually with a psychologist or psychiatrist who evaluates your history, emotional patterns, and relationships over time.
If reading the criteria above feels like someone described your inner life — particularly the combination of emotional dysregulation, disconnection from self, relationship difficulty, and a persistent sense of damage or shame — it may be worth seeking a formal evaluation. Many people with CPTSD go years without a correct diagnosis, often being treated only for depression or anxiety, or misdiagnosed with a condition that doesn’t account for the trauma history.
A few things worth knowing:
- CPTSD frequently co-occurs with ADHD, autism, and dissociative disorders. It’s common for one diagnosis to mask another, and the overlap is real — not a sign that something was misdiagnosed.
- Not everyone with CPTSD looks the same. Some people present with hyperarousal and reactivity; others have learned to suppress everything, presenting as flat, detached, or high-functioning on the surface.
- A diagnosis isn’t a verdict. It’s a lens that can help you understand your experience and access appropriate treatment.
How Buprenorphine Works
Our brains have an endogenous opioid system that helps regulate physical pain, emotional pain, attachment, and distress. Several researchers have proposed that this system can become dysregulated as a result of chronic trauma, early adversity, ongoing invalidation, or sustained inflammation.
Buprenorphine is unique because it:
-
Partially activates the mu-opioid receptor — reduces emotional and physical pain and supports social connection/seeking behavior
-
Blocks the kappa-opioid receptor — reduces dysphoria, stress-driven distress, and the aversive emotional pain response
It’s the only prescription medication that combines mu-agonism with kappa-antagonism.
Because buprenorphine is an opioid, people sometimes worry about addiction. At the very low doses studied for chronic suicidality and treatment-resistant emotional dysregulation, the addiction risk appears to be significantly lower than with full-agonist opioids, but physical dependence can still occur with long-term use. For people with a history of opioid addiction, this is an important consideration to discuss with a clinician. Many trials described their use as “time-limited,” partly because long-term data is still limited.
A Note on Dose
Most research exploring buprenorphine for chronic suicidality or related conditions in opioid-naïve patients has used sub-milligram total daily doses. In the largest controlled trial, participants began at 0.1–0.2 mg/day, administered once or twice daily, with flexible weekly titration. The mean effective dose was 0.44 mg/day, far below doses used for opioid use disorder.
Individuals without prior opioid exposure may be much more sensitive to buprenorphine. Starting at standard opioid use disorder initiation doses (e.g., 2 mg or higher) may be stronger than necessary in opioid-naïve patients and could increase side effects.
Other compounds with overlapping mechanisms:
-
Low-dose naltrexone (LDN, 0.5–4.5 mg) — at low doses, naltrexone briefly blocks opioid receptors and then appears to increase endogenous opioid activity and reduce inflammation after it wears off. This is different from the standard 50 mg dose typically used for addiction or alcohol use disorder, which produces full opioid blockade. Naltrexone is not an opioid, and LDN does not carry a risk of opioid addiction.
-
Kratom — a plant whose active alkaloids act as mu-opioid agonists with some kappa-opioid antagonism. Many people use kratom to manage pain, mood, or opioid withdrawal, and for some it’s genuinely helpful. It is weaker and shorter-acting than buprenorphine, so people often need higher and more frequent doses to get similar effects. The risk profile varies significantly by product. Traditional kratom leaf is different from concentrated extracts or high-potency 7-hydroxymitragynine (7-OH) products, which carry meaningfully higher risks of dependence and adverse effects and are currently the focus of most state-level regulatory action. Potency and purity vary widely between batches and vendors, which makes dosing harder to predict. Kratom can cause dependence and withdrawal, particularly at higher doses or with concentrated products.
I’m sharing this information for context, not as a recommendation. LDN gave me some benefit, mostly improved sleep and a small lift in mood, but it didn’t address the social connection and emotional regulation problems that made daily life difficult. Some people also experiment with kratom because it has similar receptor activity, but it carries real risks. For my own trauma-related symptoms, prescribed low-dose buprenorphine has been effective, but everyone’s response is different and access to a willing prescriber isn’t guaranteed.
Medication is highly individual. Please research carefully and talk with a clinician.